Champions Oncology Inc (CSBR) has a current Price-to-Book (P/B) ratio of 22.18. Compared to its 3-year average P/B ratio of 69.64, the current P/B ratio is approximately -68.15% higher. Relative to its 5-year average P/B ratio of 46.21, the current P/B ratio is about -52.01% higher. Champions Oncology Inc (CSBR) has a Forward Free Cash Flow (FCF) yield of approximately 6.10%. Compared to its 3-year average FCF yield of -1.68%, the current FCF yield is approximately -463.67% lower. Relative to its 5-year average FCF yield of -0.61%, the current FCF yield is about -1104.97% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CSBR competitors is 1.00, providing a benchmark for relative valuation. Champions Oncology Inc Corp (CSBR.O) exhibits a P/S ratio of 1.52, which is 51.73% above the industry average. Given its robust revenue growth of 11.46%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CSBR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CSBR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CSBR currently overvalued or undervalued?

What is Champions Oncology Inc (CSBR) fair value?

CSBR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Champions Oncology Inc (CSBR) is between 4.63 to 8.51 according to relative valuation method.

How does CSBR's valuation metrics compare to the industry average?

The average P/S ratio for CSBR's competitors is 1.00, providing a benchmark for relative valuation. Champions Oncology Inc Corp (CSBR) exhibits a P/S ratio of 1.52, which is 51.73% above the industry average. Given its robust revenue growth of 11.46%, this premium appears unsustainable.

What is the current P/B ratio for Champions Oncology Inc (CSBR) as of Mar 03 2026?

As of Mar 03 2026, Champions Oncology Inc (CSBR) has a P/B ratio of 22.18. This indicates that the market values CSBR at 22.18 times its book value.

What is the current FCF Yield for Champions Oncology Inc (CSBR) as of Mar 03 2026?

As of Mar 03 2026, Champions Oncology Inc (CSBR) has a FCF Yield of 6.10%. This means that for every dollar of Champions Oncology Inc's market capitalization, the company generates 6.10 cents in free cash flow.

What is the current Forward P/E ratio for Champions Oncology Inc (CSBR) as of Mar 03 2026?

As of Mar 03 2026, Champions Oncology Inc (CSBR) has a Forward P/E ratio of 133.20. This means the market is willing to pay $133.20 for every dollar of Champions Oncology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Champions Oncology Inc (CSBR) as of Mar 03 2026?

As of Mar 03 2026, Champions Oncology Inc (CSBR) has a Forward P/S ratio of 1.52. This means the market is valuing CSBR at $1.52 for every dollar of expected revenue over the next 12 months.

CSBR Valuation